Compare Expedia Group Inc (EXPE) vs Heron Therapeutics Inc (HRTX) Price & Performance

Expedia Group (EXPE) trades at $264.76, down 0.57% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with revenue growth to $14.73B in 2025 and consistent earnings beats, including Q1 2026 EPS of $1.96 versus $1.41 expected. Recent developments include a strategic partnership with Allegiant Travel and positive analyst coverage highlighting growth potential. Valuation metrics include a P/E of 23.6 and P/S of 2.29, indicating reasonable pricing relative to peers.

The outlook for EXPE is positive, driven by robust travel demand, strategic initiatives, and a consensus price target of $292.09 implying ~10% upside. Key risks include macroeconomic sensitivity affecting travel spending and competitive pressures. Institutional sentiment is bullish with 45% buy ratings, though investors should monitor execution on growth targets and industry cyclicality.

Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.

HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.